{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:43:36Z","timestamp":1792784616938,"version":"4.5.0"},"reference-count":47,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"Institute of Fudan University-Quzhou","id":[{"id":"https:\/\/ror.org\/013q1eq08","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["QN26H300010"],"award-info":[{"award-number":["QN26H300010"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173657"],"award-info":[{"award-number":["82173657"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Based on our previous finding that the NLRP3 inhibitor LD5 dually binds LC3 and NLRP3, we elucidated the key functional groups responsible for its engagement with NLRP3. Leveraging this insight, we designed and synthesized a library of bivalent LD5-based autophagy-targeting chimeras (ATTECs), from which M3 emerged as the most potent NLRP3 degrader. We further sought to rationalize this approach by investigating the fundamental pharmacological questions: why develop a degrader from an existing inhibitor and what advantages would such a degrader offer over the inhibitor? Comparative studies in a colitis model clearly established that the degrader M3 achieves sustained anti-inflammatory efficacy, both in vitro and in vivo, outperforming its inhibitor precursor LD5. Our study extends beyond the discovery of a potential degrader for inflammatory bowel disease to demonstrate the crucial long-lasting therapeutic advantage of degraders over inhibitors in treating this condition.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01995","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T20:02:52Z","timestamp":1791576172000},"page":"24400-24419","source":"Crossref","is-referenced-by-count":0,"title":["Beyond Inhibition: Targeted Degradation of NLRP3 by Autophagy-Tethering Bifunctional Compounds as a Therapy for Inflammatory Bowel Disease"],"prefix":"10.1021","volume":"69","author":[{"given":"Xinru","family":"Zheng","sequence":"first","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]},{"name":"Department of Pharmacy,","place":["Xiamen , China, 361023,"]},{"name":"Xiamen Medical College,","place":["Xiamen , China, 361023,"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxing","family":"Xue","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenjia","family":"Liu","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Wang","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohao","family":"Xie","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozong","family":"Ma","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7462-7266","authenticated-orcid":true,"given":"Xianfeng","family":"Gu","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Jiaxing University , , , ,","place":["Jiaxing, Zhejiang, China, 314000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Fudan University , , ,","place":["Shanghai, China, 201301"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"issue":"4","key":"2026102305082098700_cit1","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2016.03.046","article-title":"Inflammasome Complexes: Emerging Mechanisms and Effector Functions","volume":"165","author":"Rathinam","year":"2016","journal-title":"Cell"},{"issue":"16","key":"2026102305082098700_cit2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1016\/j.cell.2024.07.010","article-title":"From periphery to center stage: 50 years of advancements in innate immunity","volume":"187","author":"Carpenter","year":"2024","journal-title":"Cell"},{"issue":"26","key":"2026102305082098700_cit3","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1016\/j.cell.2021.11.035","article-title":"Caging NLRP3 tames inflammasome activity","volume":"184","author":"Schroder","year":"2021","journal-title":"Cell"},{"issue":"8","key":"2026102305082098700_cit4","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat. Rev. Immunol."},{"issue":"26","key":"2026102305082098700_cit5","doi-asserted-by":"publisher","first-page":"6299","DOI":"10.1016\/j.cell.2021.11.011","article-title":"NLRP3 cages revealed by full-length mouse NLRP3 structure control pathway activation","volume":"184","author":"Andreeva","year":"2021","journal-title":"Cell"},{"key":"2026102305082098700_cit6","doi-asserted-by":"publisher","first-page":"1074606","DOI":"10.3389\/fimmu.2023.1074606","article-title":"NLRP3 inflammasome-induced pyroptosis in digestive system tumors","volume":"14","author":"Wen","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"2026102305082098700_cit7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","article-title":"The role of inflammasomes in human diseases and their potential as therapeutic targets","volume":"9","author":"Yao","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"12","key":"2026102305082098700_cit8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41419-019-2157-1","article-title":"NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-\u03baB signaling","volume":"10","author":"Chen","year":"2019","journal-title":"Cell Death Dis."},{"issue":"9","key":"2026102305082098700_cit9","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.3390\/ijms24098162","article-title":"Portrayal of NLRP3 Inflammasome in Atherosclerosis: Current Knowledge and Therapeutic Targets","volume":"24","author":"Tanase","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7784","key":"2026102305082098700_cit10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","article-title":"NLRP3 inflammasome activation drives tau pathology","volume":"575","author":"Ising","year":"2019","journal-title":"Nature"},{"issue":"15","key":"2026102305082098700_cit11","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.neuron.2022.05.009","article-title":"Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson\u2019s disease","volume":"110","author":"Panicker","year":"2022","journal-title":"Neuron"},{"issue":"1","key":"2026102305082098700_cit12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"2026102305082098700_cit13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1124\/pharmrev.120.000171","article-title":"Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950","volume":"73","author":"Corcoran","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"9","key":"2026102305082098700_cit14","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"12","key":"2026102305082098700_cit15","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1021\/acs.jmedchem.8b00733","article-title":"Structural Insights of Benzenesulfonamide Analogues as NLRP3 Inflammasome Inhibitors: Design, Synthesis, and Biological Characterization","volume":"61","author":"Fulp","year":"2018","journal-title":"J. Med. Chem."},{"issue":"18","key":"2026102305082098700_cit16","doi-asserted-by":"publisher","first-page":"16612","DOI":"10.1021\/acs.jmedchem.4c01445","article-title":"Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"17","key":"2026102305082098700_cit17","doi-asserted-by":"publisher","first-page":"15711","DOI":"10.1021\/acs.jmedchem.4c01341","article-title":"Discovery of Potent, Specific, and Orally Available NLRP3 Inflammasome Inhibitors Based on Pyridazine Scaffolds for the Treatment of Septic Shock and Peritonitis","volume":"67","author":"Fu","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026102305082098700_cit18","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1021\/acsmedchemlett.2c00242","article-title":"Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome Inhibitors","volume":"13","author":"Harrison","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"23","key":"2026102305082098700_cit19","doi-asserted-by":"publisher","first-page":"16141","DOI":"10.1021\/acs.jmedchem.3c01511","article-title":"Discovery of Novel 2,3-Dihydro-1H-indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis","volume":"66","author":"Sun","year":"2023","journal-title":"J. Med. Chem."},{"issue":"43","key":"2026102305082098700_cit20","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202405860","article-title":"Discovery, Total Synthesis, and Anti-Inflammatory Evaluation of Naturally Occurring aphthopyrone-Macrolide Hybrids as Potent NLRP3 Inflammasome Inhibitors","volume":"63","author":"Sun","year":"2024","journal-title":"Angew. Chem. Int. Ed."},{"issue":"11","key":"2026102305082098700_cit21","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.1021\/acs.jmedchem.4c00504","article-title":"Hit-to-Lead Optimization of the Natural Product Oridonin as Novel NLRP3 Inflammasome Inhibitors with Potent Anti-Inflammation Activity","volume":"67","author":"He","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"2026102305082098700_cit22","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1038\/s41401-024-01434-1","article-title":"Hypocrellin A from an ethnic medicinal fungus protects against NLRP3-driven gout in mice by suppressing inflammasome activation","volume":"46","author":"Yan","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"issue":"18","key":"2026102305082098700_cit23","doi-asserted-by":"publisher","first-page":"13633","DOI":"10.1021\/acs.jmedchem.1c01007","article-title":"Discovery of Novel Pterostilbene-Based Derivatives as Potent and Orally Active NLRP3 Inflammasome Inhibitors with Inflammatory Activity for Colitis","volume":"64","author":"Chen","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026102305082098700_cit24","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s42003-026-09524-y","article-title":"Nimbolide ameliorates ARDS and ulcerative colitis by disrupting NLRP3 inflammasome activation","volume":"9","author":"Xu","year":"2026","journal-title":"Commun. Biol."},{"issue":"2","key":"2026102305082098700_cit25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"2026102305082098700_cit26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10822-019-00197-w","article-title":"Elucidating the druggability of the human proteome with eFindSite","volume":"33","author":"Kana","year":"2019","journal-title":"J. Comput.-Aided Mol. Des."},{"issue":"1","key":"2026102305082098700_cit27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-022-00966-4","article-title":"Targeted protein degradation: mechanisms, strategies and application","volume":"7","author":"Zhao","year":"2022","journal-title":"Signal Transduction Targeted Ther."},{"issue":"11","key":"2026102305082098700_cit28","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.scib.2024.03.056","article-title":"Targeting the undruggables \ue5f8the power of protein degraders","volume":"69","author":"Zhang","year":"2024","journal-title":"Sci. Bull."},{"issue":"1","key":"2026102305082098700_cit29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ph17010100","article-title":"From PROTAC to TPD: Advances and Opportunities in Targeted Protein Degradation","volume":"17","author":"Wang","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"7","key":"2026102305082098700_cit30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41568-025-00817-8","article-title":"Targeted protein degradation for cancer therapy","volume":"25","author":"Hinterndorfer","year":"2025","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"2026102305082098700_cit31","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1021\/acscentsci.2c01317","article-title":"Rational Chemical Design of Molecular Glue Degraders","volume":"9","author":"Toriki","year":"2023","journal-title":"ACS Cent. Sci."},{"issue":"14","key":"2026102305082098700_cit32","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1039\/d4cc06321j","article-title":"Degrading the key component of the inflammasome: development of an NLRP3 PROTAC","volume":"61","author":"Keuler","year":"2025","journal-title":"Chem. Commun."},{"issue":"7781","key":"2026102305082098700_cit33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-019-1722-1","article-title":"Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds","volume":"575","author":"Li","year":"2019","journal-title":"Nature"},{"issue":"50","key":"2026102305082098700_cit34","doi-asserted-by":"publisher","first-page":"26105","DOI":"10.1002\/anie.202109464","article-title":"Inhibition of Autophagy by a Small Molecule through Covalent Modification of the LC3 Protein","volume":"60","author":"Fan","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"issue":"97","key":"2026102305082098700_cit35","doi-asserted-by":"publisher","first-page":"13194","DOI":"10.1039\/d1cc04661f","article-title":"Developing potent LC3-targeting AUTAC tools for protein degradation with selective autophagy","volume":"57","author":"Pei","year":"2021","journal-title":"Chem. Commun."},{"key":"2026102305082098700_cit36","doi-asserted-by":"publisher","first-page":"7619","DOI":"10.1021\/acs.jmedchem.1c02001","article-title":"Ispinesib as an Effective Warhead for the Design of Autophagosome-Tethering Chimeras: Discovery of Potent Degraders of Nicotinamide Phosphoribosyltransferase (NAMPT)","volume":"65","author":"Dong","year":"2022","journal-title":"J. Med. Chem."},{"key":"2026102305082098700_cit37","doi-asserted-by":"publisher","first-page":"12877","DOI":"10.1021\/acs.jmedchem.3c00828","article-title":"Degradation of Cyclin-Dependent Kinase 9\/Cyclin T1 by Optimized Microtubule-Associated Protein 1 Light Chain 3 Beta-Recruiting Coumarin Analogs","volume":"66","author":"Zeng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026102305082098700_cit38","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1016\/j.scib.2023.10.021","article-title":"Targeted clearance of mitochondria by an autophagy-tethering compound (ATTEC) and its potential therapeutic effects","volume":"68","author":"Tan","year":"2023","journal-title":"Sci. Bull."},{"issue":"9","key":"2026102305082098700_cit39","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41422-021-00532-7","article-title":"Degradation of lipid droplets by chimeric autophagy-tethering compounds","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res."},{"issue":"12","key":"2026102305082098700_cit40","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1080\/15548627.2021.1967616","article-title":"Targeting lipid droplets for autophagic degradation by ATTEC","volume":"17","author":"Fu","year":"2021","journal-title":"Autophagy"},{"issue":"1","key":"2026102305082098700_cit41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.jmedchem.3c01634","article-title":"Targeted Degradation of PCSK9 In Vivo by Autophagy-Tethering Compounds","volume":"67","author":"Ouyang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026102305082098700_cit42","doi-asserted-by":"publisher","first-page":"8190","DOI":"10.1021\/acs.jmedchem.4c02915","article-title":"PCSK9 Targeted Autophagosome-Tethering Compounds: Design, Synthesis, and Antiatherosclerosis Evaluation","volume":"68","author":"Wu","year":"2025","journal-title":"J. Med. Chem."},{"key":"2026102305082098700_cit43","doi-asserted-by":"publisher","first-page":"116581","DOI":"10.1016\/j.ejmech.2024.116581","article-title":"Discovery of autophagy-tethering compounds as potent NLRP3 degraders for IBD Immunotherapy","volume":"275","author":"Yin","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"20","key":"2026102305082098700_cit44","doi-asserted-by":"publisher","first-page":"10755","DOI":"10.1021\/acs.analchem.5c00941","article-title":"A pH-Sensitive NIR Fluorescent Probe as a Protagonist in the Discovery of New LC3 Ligands Facilitating the Construction of ATTECs","volume":"97","author":"Xie","year":"2025","journal-title":"Anal. Chem."},{"issue":"8","key":"2026102305082098700_cit45","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1021\/acsmedchemlett.3c00311","article-title":"Pyridazine Derivatives as NLRP3 Inhibitors for Treating Asthma, COPD, Parkinson\u2019s Disease, and Alzheimer\u2019s Disease","volume":"14","author":"Sabnis","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"4","key":"2026102305082098700_cit46","doi-asserted-by":"publisher","first-page":"4848","DOI":"10.1021\/acs.jmedchem.4c03108","article-title":"Discovery of Potent and Brain-Penetrant Bicyclic NLRP3 Inhibitors with Peripheral and Central In Vivo Activity","volume":"68","author":"Mammoliti","year":"2025","journal-title":"J. Med. Chem."},{"issue":"23","key":"2026102305082098700_cit47","doi-asserted-by":"publisher","first-page":"20780","DOI":"10.1021\/acs.jmedchem.4c02350","article-title":"Discovery of NP3-253, a Potent Brain Penetrant Inhibitor of the NLRP3 Inflammasome","volume":"67","author":"Mackay","year":"2024","journal-title":"J. Med. Chem."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01995","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24400\/68807572\/jm6c01995.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24400\/68807572\/jm6c01995.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:23:38Z","timestamp":1792747418000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24400\/5448299\/Beyond-Inhibition-Targeted-Degradation-of-NLRP3-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":47,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,9]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01995","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}